OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

Aurobindo arm CuraTeQ receives Health Canada approval for bevacizumab biosimilar Bevqolva

Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market

OneSource Specialty Pharma's partners get Health Canada approval for generic Semaglutide injection

Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing

Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection

Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada

OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide

Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility

Biocon receives Health Canada approval for Bosaya and Vevzuo biosimilars to Prolia and Xgeva

Denosumab biosimilars approved in Canada to expand access for osteoporosis and cancer-related bone conditions

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026

Univar Solutions bags exclusive US & Canada deal for Ingredion Pharmaceutical starches

Lupin partners with Spektus Pharma to commercialize DeslaFlex antidepressant in Canada

DeslaFlex is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab oral drug-delivery platform

Zydus and Formycon secure US and Canada partnership for Keytruda biosimilar

Formycon AG will develop, register, manufacture and supply the product, while Zydus Lifesciences Global FZE, United Arab Emirates will be responsible for the commercialization of FYB206 in the defined territories